Ana Lluch (A Lluch)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 21

Top Venues

NPJ breast cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Cell death discovery

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Sara S Oltra, Sara Colomo, Laura Sin, María Pérez-López, Sara Lázaro, Angela Molina-Crespo, Kyoung-Han Choi, David Ros-Pardo, Lidia Martínez, Saleta Morales, Cristina González-Paramos, Alba Orantes, Mario Soriano, Alberto Hernández, Ana Lluch, Federico Rojo, Joan Albanell, Paulino Gómez-Puertas, Jae-Kyun Ko, David Sarrió, Gema Moreno-Bueno
Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells. Cell death and differentiation (2023)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 9 (1) (2023)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 9 (1) (2023)
David Casadevall, Anna Hernández-Prat, Sara García-Alonso, Oriol Arpí-Llucià, Silvia Menéndez, Mengjuan Qin, Cristina Guardia, Beatriz Morancho, Francisco Javier Sánchez-Martín, Sandra Zazo, Elena Gavilán, Mohammad A Sabbaghi, Pilar Eroles, Juan Miguel Cejalvo, Ana Lluch, Federico Rojo, Atanasio Pandiella, Ana Rovira, Joan Albanell
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular cancer research : MCR 20 (7) (2022)
S Mouron, Maria Jose Bueno, Ana Lluch, Luis Manso Sanchez, I Calvo, Javier Cortes, José Angel García-Saenz, M Gil-Gil, N Martinez-Janez, J V Apala, E Caleiras, Pilar Ximénez-Embún, J Muñoz, L Gonzalez-Cortijo, R Murillo, R Sánchez-Bayona, J M Cejalvo, G Gómez-López, Coral Fustero-Torre, Sergio Sabroso-Lasa, Núria Malats, M Martinez, A Moreno, D Megias, Marcos Malumbres, Ramón Colomer, Miguel Quintela-Fandino
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nature communications 13 (1) (2022)
Karama Asleh, Ana Lluch, Angela Goytain, Carlos Henrique Barrios, Xue Qi Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruiz Borrego, Samuel C Y Leung, Jose Bines, Angel L Guerrero-Zotano, José Angel García-Saenz, Juan Miguel Cejalvo, Jesus Herranz, Roberto Torres, Juan R De la Haba-Rodríguez, Francisco Ayala, Henry L Gómez, Federico Rojo, Torsten O Nielsen, Miguel Martin
Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Anna Adam-Artigues, Enrique J Arenas Lahuerta, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez Martínez, Juan Antonio Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science advances 8 (20) (2022)
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M Schram, Helen Ambrose, T Hedley Carr, Elza C de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M Hyman, Sarat Chandarlapaty
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ breast cancer 7 (1) (2021)
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (18) (2021)
Anna Adam-Artigues, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, Ana Lameirinhas, Soraya Simón, Belén Ortega-Morillo, María Teresa Martínez, Cristina Hernando, Vera Constâncio, Octavio Burgues, Begoña Bermejo, Rui M Henrique, Ana Lluch, Carmen Jerónimo, Pilar Eroles, Juan Miguel Cejalvo
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers 13 (11) (2021)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, María Jesús Vidal Losada, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos Henrique Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ breast cancer 7 (1) (2021)
Iris Garrido-Cano, Vera Constâncio, Anna Adam-Artigues, Ana Lameirinhas, Soraya Simón, Belen Ortega, María Teresa Martínez, Cristina Hernando, Begoña Bermejo, Ana Lluch, Paula Lopes, Rui Henrique, Carmen Jerónimo, Juan Miguel Cejalvo, Pilar Eroles
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. International journal of molecular sciences 21 (19) (2020)
Sandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, Cristina Chamizo, Melani Luque, Marta Sanz-Álvarez, Pablo Mínguez, Gonzalo Gómez-López, Pilar Eroles, Cristina Caramés, Jesús García-Foncillas, Ana Lluch, Oriol Arpí, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. Molecular cancer therapeutics 19 (8) (2020)
Sara S Oltra, Juan Miguel Cejalvo, Eduardo Tormo, Marta Albanell, Ana Ferrer, Marta Nacher, Begoña Bermejo, Cristina Hernando, Isabel Chirivella, Elisa Alonso, Octavio Burgués, Maria Peña-Chilet, Pilar Eroles, Ana Lluch, Gloria Ribas, María Teresa Martinez
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers 12 (2) (2020)
Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, Anna López-Plana, Patricia Jauregui, Vanesa Almendro, Estel Enreig, Silvia Menéndez, Federico Rojo, Aleix Noguera-Castells, Anke Bill, L Alex Gaither, Laia Serrano, Leire Recalde-Percaz, Núria Moragas, Raul Alonso, Elisabet Ametller, Ana Rovira, Ana Lluch, Joan Albanell, Pere Gascon, Paloma Bragado
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6) (2019)
Eduardo Tormo, Sandra Ballester, Anna Adam-Artigues, Octavio Burgués, Elisa Alonso, Begoña Bermejo, Silvia Menéndez, Sandra Zazo, Juan Madoz-Gúrpide, Ana Rovira, Joan Albanell, Federico Rojo, Ana Lluch, Pilar Eroles
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Scientific reports 9 (1) (2019)
Aura Muntasell, Sònia Servitja, Mariona Cabo, Begoña Bermejo, Sandra Pérez-Buira, Federico Rojo, Marcel Costa-García, Oriol Arpí, Manuela Moraru, Laia Serrano, Ignasi Tusquets, María Teresa Martínez Martínez, Gemma Heredia, Andrea Vera, María Martínez-García, Laura Soria, Laura Comerma, Sara Santana-Hernández, Pilar Eroles, Ana Rovira, Carlos Vilches, Ana Lluch, Joan Albanell, Miguel López-Botet
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer immunology research 7 (8) (2019)
Aura Muntasell, Federico Rojo, Sonia Servitja, Carlota Rubio-Perez, Mariona Cabo, David Tamborero, Marcel Costa-García, Maria Martinez-García, Sílvia Menéndez, Ivonne Vazquez, Ana Lluch, Abel Gonzalez-Perez, Ana Rovira, Miguel López-Botet, Joan Albanell
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (5) (2018)

Ana Lluch.css-eqlu8i{font-size:small;padding-left:4px;} (A Lluch)

Publication Activity (10 Years)

Top Topics

Top Venues

Ana Lluch (A Lluch)